By Lina carolina 
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have identified a crucial protein marker, CD74, that could significantly broaden the eligibility for life-saving immunotherapy treatments in patients with bowel cancer. This groundbreaking discovery, published in the prestigious journal Cancer Cell, suggests that measuring CD74 levels could enable hundreds of individuals, previously considered ineligible for immunotherapy, to benefit from this revolutionary approach to cancer treatment. The implications are far-reaching, potentially transforming the therapeutic landscape for a substantial proportion of bowel cancer patients, particularly those with the proficient subtype.
Bowel cancer, a devastating disease that ranks as the fourth most common cancer and the second leading cause of cancer-related mortality in the United Kingdom, presents a complex clinical challenge. The disease is broadly categorized into two distinct subtypes based on the integrity of DNA repair mechanisms. The "deficient subtype" is characterized by missing or impaired proteins responsible for correcting errors in DNA, while the "proficient subtype" possesses intact DNA repair machinery.
Immunotherapy, a powerful class of drugs designed to harness and amplify the body’s own immune system to combat cancerous cells, has already revolutionized the treatment of the deficient subtype of colorectal cancer. These treatments have offered new hope and extended survival for many patients. However, the efficacy of current immunotherapies is limited, working effectively in only about half of the individuals diagnosed with the deficient subtype. More critically, patients with the proficient subtype, who constitute approximately 90% of all bowel cancer cases, are currently excluded from immunotherapy treatment protocols, leaving them with fewer advanced therapeutic options. This disparity highlights a significant unmet need in the management of bowel cancer.
The research initiative, undertaken by a collaborative team of scientists, aimed to unravel the complex biological factors that dictate response to immunotherapy and to identify potential strategies for expanding its applicability. Their investigation focused on the intricate interplay between the tumor microenvironment and the immune system’s ability to mount an effective anti-cancer response.
Unraveling the Immune Microenvironment’s Role in Immunotherapy Response
A key focus of the research was to meticulously examine the immune cells that infiltrate the vicinity of different bowel tumors. The presence, type, and spatial arrangement of these immune cells are known to profoundly influence a patient’s response to immunotherapy. The scientists analyzed tissue samples from both deficient and proficient subtypes, comparing individuals who responded positively to immunotherapy drugs with those who did not achieve a therapeutic benefit.
Their detailed analysis revealed a critical requirement for the co-existence and proximity of three specific types of immune cells within the tumor microenvironment for immunotherapy to be successful. These essential cellular players include cytotoxic T cells, often referred to as "fighter cells," which are directly responsible for identifying and destroying cancer cells. Alongside T cells, Natural Killer (NK) cells, another potent component of the innate immune system, were found to be crucial. The third vital component identified was macrophages, a type of white blood cell that plays a dual role: they can engulf and clear cellular debris and pathogens, and critically, they act as antigen-presenting cells, displaying fragments of foreign or abnormal cells (like cancer cells) on their surfaces as "flags" to alert and activate other immune cells, thereby highlighting a threat to the body.
When these three immune cell populations – T cells, NK cells, and macrophages – were found to be present and in close proximity to cancer cells, a significant cascade of immune signaling was observed. Specifically, the T cells released molecules known as interferons. These interferons, acting as crucial signaling molecules, then triggered a downstream response in both macrophages and the tumor cells themselves. This intricate communication pathway appeared to be a prerequisite for initiating a robust anti-tumor immune response.
The study found that this signaling pathway was significantly amplified in tumors of the deficient subtype that responded to immunotherapy. However, in a discovery that has profound clinical implications, the researchers observed that a subset of patients within the proficient subtype also exhibited a comparable level of this crucial immune signaling. This finding was particularly striking, suggesting that their immune systems might already be primed and poised to benefit from immunotherapy, even though they fall into a category currently excluded from such treatments. This observation provided the first tantalizing clue that subtype alone might not be the definitive determinant of immunotherapy response.
CD74: A Predictive Biomarker for Immunotherapy Success
Building upon the insights gained from analyzing the immune microenvironment, the research team sought a more direct and clinically applicable method to ascertain whether a patient’s immune system was sufficiently prepared for immunotherapy. Their quest led them to investigate the expression levels of specific proteins that could serve as reliable indicators.
Employing a cutting-edge technology known as spatial transcriptomics, which allows for the detailed analysis of gene expression within specific locations in a tissue sample, the scientists made a pivotal discovery. They observed that stimulated T cells were actively promoting the production of a protein called CD74 in nearby macrophages and tumor cells. Crucially, tumors that were demonstrably responding to immunotherapy drugs consistently exhibited higher levels of CD74 expression. This correlation suggested that CD74 might serve as a direct readout of the activated immune signaling cascade observed earlier.
To rigorously test the potential of CD74 as a clinical marker for predicting immunotherapy response, the researchers expanded their investigation to include samples from several international clinical trials. These trials specifically focused on evaluating immunotherapy in patient cohorts with the proficient subtype of bowel cancer. The results from these independent datasets were highly consistent and compelling. Patients who responded favorably to immunotherapy treatments displayed significantly higher levels of CD74 in their tumors compared to those who did not experience a clinical benefit.
These findings strongly indicate that measuring CD74 protein levels in tumor biopsies could serve as a reliable predictor of an individual’s response to immunotherapy, irrespective of their specific bowel cancer subtype. This is a monumental shift from the current paradigm, where subtype classification has been a primary determinant of eligibility.
Transforming Treatment Access and Patient Outcomes
The implications of this discovery are profound. Currently, the vast majority of bowel cancer patients, those with the proficient subtype, are ineligible for immunotherapy. This new research suggests that a significant portion of these patients, identified by elevated CD74 levels, could potentially benefit from these life-saving treatments. This could represent a substantial increase in the number of patients eligible for immunotherapy, potentially numbering in the hundreds across the UK alone, based on the prevalence of the proficient subtype.
Dr. Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, emphasized the transformative potential of this discovery. "Immunotherapy drugs can be hugely successful for people with bowel cancer," she stated, "but currently, the majority of patients can’t be prescribed these drugs, and even when patients are eligible, we don’t know upfront who will respond. Our work suggests that testing for CD74 levels – which signal that the immune system is ‘just right’ to fight the tumour – could widen access to immunotherapy. This could revolutionize treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily."
The ability to predict non-response is as significant as predicting response. For patients with the deficient subtype who are currently eligible but unlikely to benefit from immunotherapy, identifying this lack of response through CD74 testing could prevent them from undergoing treatments that are not only ineffective but also carry the risk of debilitating side effects. This personalized approach to treatment selection could significantly improve the quality of life for these individuals.
Kalum Clayton, a former postdoc at the Crick and joint first author of the study, highlighted the power of advanced technologies in addressing critical clinical questions. "Our work shows how state-of-the-art technologies coupled with computational analysis can address important clinical questions," he remarked. "As an early career research scientist, seeing the potential of our work to provide benefit to patients and their families is greatly rewarding." His sentiment underscores the dedication and passion driving scientific advancement towards tangible patient benefit.
The Path Forward: From Discovery to Clinical Application
The research team is not resting on their laurels. They are actively collaborating with Cancer Research Horizons, the commercialization arm of Cancer Research UK, to translate these promising findings into a clinically viable diagnostic test. This process involves rigorous validation and the development of standardized protocols to ensure the test’s reliability and accessibility in routine clinical practice.
Furthermore, the researchers are delving deeper into the underlying biological mechanisms. They aim to understand precisely why macrophages and tumor cells upregulate CD74 expression in response to immune stimulation. This deeper understanding could potentially lead to the development of novel therapeutic strategies that could further enhance immunotherapy efficacy or even create new treatment avenues. The team also plans to investigate whether CD74 serves as a similar predictive marker in other types of cancer, potentially expanding its impact across a wider range of malignancies.
Anna Kinsella, Science Engagement Manager at Cancer Research UK, lauded the study’s contribution to the ongoing fight against cancer. "Immunotherapy treatments, such as immune checkpoint inhibitors, use the power of the immune system to fight cancer," she explained. "Whilst these treatments benefit some people with bowel cancer, they aren’t effective for everyone. Although further research is needed, studies like this – diving deep into the biology of tumours – help researchers find ways to predict when immunotherapy is likely to work. In the future, this could help clinicians tailor treatment and allow more people with bowel cancer to benefit from immunotherapy." She reiterated Cancer Research UK’s commitment to discovery research, stating, "Understanding the biology of cancer is vital to unlocking better ways to prevent, detect and treat it, so that people can live longer, better lives free from the fear of cancer. That’s why at Cancer Research UK, discovery research is at the heart of everything we do."
The collaborative nature of this research is also noteworthy, with contributions from institutions including UCL, the University of Pisa, King’s College London, the Sarah Cannon Research Institute, and the Veneto Institute of Oncology. This broad scientific partnership underscores the global effort required to tackle complex diseases like cancer.
Broader Implications and Future Directions
The identification of CD74 as a predictive biomarker for immunotherapy response in bowel cancer represents a significant step forward in precision oncology. It moves beyond broad categorizations of cancer into more nuanced, biology-driven approaches to treatment selection. This shift is emblematic of a broader trend in cancer research: leveraging advanced technologies like spatial transcriptomics to uncover intricate cellular and molecular interactions that were previously invisible.
The potential to expand immunotherapy access to an additional 90% of bowel cancer patients, even a fraction of that, is a game-changer. It means that more individuals could experience the profound benefits of treatments that have demonstrated remarkable success in treating advanced cancers. The economic and societal implications are also considerable, with the potential for increased survival rates, improved quality of life, and reduced healthcare burdens associated with less effective treatments.
While the findings are highly promising, the journey from laboratory discovery to widespread clinical implementation requires further validation and regulatory approval. The ongoing work by the research team and their commercial partners will be crucial in bringing this diagnostic tool to the bedside. Future research will undoubtedly explore the precise mechanisms by which CD74 influences the tumor immune microenvironment and investigate its potential role in other cancer types. The ongoing evolution of immunotherapy and the quest for more effective and personalized cancer treatments remain a vibrant and critical area of scientific endeavor, and the discovery of CD74 is a beacon of hope in this ongoing battle.